Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > LATEST
LATEST
-
BUSINESS Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
-
REGULATORY MHLW Gathers 140 Proposals for New Elective Care Items: Chuikyo
September 18, 2025
-
REGULATORY J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
-
BUSINESS Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
-
ORGANIZATION JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
-
BUSINESS Kyorin/aTyr’s Efzofitimod Misses Primary Goal in Global PIII Trial
September 17, 2025
-
BUSINESS Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
-
BUSINESS ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
-
REGULATORY Japan Confirms First Case of Mpox Clade 1b
September 17, 2025
-
BUSINESS Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
-
REGULATORY MHLW Withdraws Sakigake Tag for Takeda’s TAK-925
September 17, 2025
-
ORGANIZATION JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
-
REGULATORY Health Minister Avoids Speculation on Impact of US Drug Price Cuts
September 16, 2025
-
BUSINESS AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
-
BUSINESS Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
-
BUSINESS Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
-
BUSINESS Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
REGULATORY Tensions Flare at Chuikyo over Premiums for Generic Dispensing
September 16, 2025
-
BUSINESS Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…